HRMY has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
HRMY has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Harmony Biosciences Holdings's yield on cost for the quarter that ended in Dec. 2024 was 0.00.
The historical rank and industry rank for Harmony Biosciences Holdings's 5-Year Yield-on-Cost % or its related term are showing as below:
For the Biotechnology subindustry, Harmony Biosciences Holdings's 5-Year Yield-on-Cost %, along with its competitors' market caps and 5-Year Yield-on-Cost % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, Harmony Biosciences Holdings's 5-Year Yield-on-Cost % distribution charts can be found below:
* The bar in red indicates where Harmony Biosciences Holdings's 5-Year Yield-on-Cost % falls into.
Dividend Yield % and dividend growth of a stock is an important factor for income investors. But if company A raises its dividend constantly faster than company B, company A's future dividend yield might be much higher than Company B's even if their yields are the same now and their stock prices do not change.
Yield on Cost assumes that you buy and the stock today, and hold it for 5 years. If the company raises it dividends at the same rate as it did over the past 5 years, the dividends investors receive annually in 5 years relative to the stock price today.
Therefore, Yield-on-Cost of Harmony Biosciences Holdings is calculated as
Yield-on-Cost | = | Dividend Yield % | * | (1 | + | Dividend Growth Rate)^5 |
Harmony Biosciences Holdings (NAS:HRMY) 5-Year Yield-on-Cost % Explanation
Of course the risk here is that the company may not raise its dividends as it did before. The key is to select the companies that can consistently raise its dividends. Usually companies with long history of raising dividends tend to do so.
Thank you for viewing the detailed overview of Harmony Biosciences Holdings's 5-Year Yield-on-Cost % provided by GuruFocus.com. Please click on the following links to see related term pages.
Jeffrey Dierks | officer: Chief Commercial Officer | 630 W. GERMANTOWN PIKE, SUITE 215, PLYMOUTH MEETING PA 19462 |
Sandip Kapadia | officer: Chief Financial Officer | 450 WEST 15 STREET, SUITE 505, NEW YORK NY 10011 |
Jeffrey M. Dayno | officer: Chief Medical Officer | 460 EAST SWEDESFORD ROAD, SUITE 1050, WAYNE PA 19087 |
Marshman Fund Trust Ii | 10 percent owner | 630 W. GERMANTOWN PIKE, SUITE 215, PLYMOUTH MEETING PA 19462 |
Valor Iv Pharma Holdings, Llc | 10 percent owner | 875 N. MICHIGAN AVENUE, SUITE 3214, CHICAGO IL 60611 |
Peter Anastasiou | director | C/O HARMONY BIOSCIENCES HOLDINGS, INC., 630 W. GERMANTOWN PIKE, SUITE 215, PLYMOUTH MEETING PA 19462 |
Andreas Wicki | director | C/O HBM BIOVENTURES (CAYMAN) LTD., CENTENNIAL TOWERS,STE.305,2454 W.BAY RD., GRAND CAYMAN E9 E9 |
Jack Nielsen | director | C/O AKEBIA THERAPEUTICS, INC., 245 FIRST STREET, SUITE 1100, CAMBRIDGE MA 02142 |
Andrew Serafin | officer: Chief Business Officer | 630 W. GERMANTOWN PIKE, PLYMOUTH MEETING PA 19462 |
John C Jacobs | director, officer: President, CEO | 630 W. GERMANTOWN PIKE, SUITE 215, PLYMOUTH MEETING PA 19462 |
Linda M Szyper | director | C/O NEOS THERAPEUTICS, INC., 2940 N. HIGHWAY 250, SUITE 400, GRAND PRAIRIE TX 75050 |
Eric L Motley | director | 1516 33RD STREET NW, WASHINGTON DC 20007 |
R. Mark Graf | director | C/O DISCOVER FINANCIAL SERVICES, 2500 LAKE COOK ROAD, RIVERWOODS IL 60015 |
Novo Holdings A/s | 10 percent owner | TUBORG HAVNEVEJ 19, HELLERUP G7 2900 |
Valor Management L.p. | 10 percent owner | 875 N. MICHIGAN AVENUE, SUITE 3214, CHICAGO IL 60611 |
From GuruFocus
By GuruFocus News • 01-31-2025
By PRNewswire • 06-24-2024
By PRNewswire • 12-03-2024
By PRNewswire • 10-31-2024
By Marketwired • 08-06-2024
By PRNewswire • 08-21-2024
By Business Wire • 02-19-2025
By PRNewswire • 10-29-2024
By Business Wire • 01-13-2025
By Business Wire • 02-18-2025
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.